Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Efficacy of Sertraline in Prevention of Depression Recurrence in Older Versus Younger Adults With Diabetes
Monique M. Williams,Ray E. Clouse,Billy D. Nix,Eugene H. Rubin,Gregory S. Sayuk,Janet B. McGill,Alan J. Gelenberg,Paul Ciechanowski,Irl B. Hirsch,Patrick J. Lustman +9 more
TL;DR: In this paper, the authors used Cox proportional hazards models to determine differences in time to depression recurrence between treatment arms (sertraline or placebo) for each age subset and between age subsets for each treatment.
38
Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
TL;DR: In this article, the frequency of the initial short-term decline in estimated glomerular filtration rate (eGFR), eGFR dip, following initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and i...
Late-Onset T1DM and Older Age Predict Risk of Additional Autoimmune Disease.
Jing W. Hughes,Yicheng K. Bao,Yicheng K. Bao,Maamoun Salam,Prajesh Joshi,Prajesh Joshi,C. Rachel Kilpatrick,Kavita Juneja,David Nieves,David Nieves,Victoria E Bouhairie,Victoria E Bouhairie,Olivia J. Jordan,Olivia J. Jordan,Erica C. Blustein,Erica C. Blustein,Garry S. Tobin,Janet B. McGill +17 more
TL;DR: Later onset of T1DM is an independent and significant risk factor for developing additional AIDs and individuals who are diagnosed with T1 DM at older ages, particularly women, should be monitored for other autoimmune conditions.
36
Improving microvascular outcomes in patients with diabetes through management of hypertension.
TL;DR: A review of clinical trials in the context of BP control, diabetes, and the microvascular complications of retinopathy and nephropathy finds promising data with renin-angiotensin-aldosterone system (RAAS) inhibitors.
36
Type 2 diabetes, obesity, and sex difference affect the fate of glucose in the human heart
Linda R. Peterson,Pilar Herrero,Andrew R. Coggan,Zulia Kisrieva-Ware,Ibrahim M. Saeed,Carmen S. Dence,Deborah Koudelis,Janet B. McGill,Matthew R. Lyons,Eric Novak,Victor G. Davila-Roman,Alan D. Waggoner,Robert J. Gropler +12 more
TL;DR: In this paper, the authors measured intramyocardiocellular glucose metabolism from time-activity curves generated from previously obtained positron emission tomography scans of 110 subjects in three groups: nonobese, obese, and diabetes.
35